We did not characterize the downstream pathways because we focused on testing whether enhanced Rac1-dependent active forgetting contributes to AD-related “memory loss” and whether the inhibition of Rac1 activity may be an effective treatment for memory-associated symptoms. This evidence concerns the gene RAC1 and Alzheimer disease.